{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"51.8","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"description":"Percent of patients and the 95% Binomial Confidence interval who had any chronic GvHD reported based on Filipovich et al. consensus document (BB\\&MT 2005) and Akpek et al. chronic GvHD grading system (Blood 2003) for patients in Phase II.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard treatment of sirolimus and tacrolimus as GvHD prophylaxis with sirolimus (target plasma drug level of 5-10 ng/ml) and lenalidomide (15 mg daily) as post-transplant maintenance","id":"OG000","title":"Phase II"}],"paramType":"NUMBER","populationDescription":"All patients who received treatment and were followed after transplant","reportingStatus":"POSTED","timeFrame":"Transplant (Day 0) through 1 year post-transplant","title":"Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}